Daclizumab

• CAT Number: M095057
• CAS Number: 152923-56-3
• Purity: ≥95%

Daclizumab（Cat No.:M095057）is a monoclonal antibody that targets the interleukin-2 receptor alpha chain (CD25), which is involved in the activation of T-cells. By binding to CD25, Daclizumab inhibits T-cell activation, making it useful in treating autoimmune diseases, particularly multiple sclerosis. It has been shown to reduce inflammation and prevent the destruction of nerve cells. Daclizumab was also studied in organ transplant settings to prevent rejection. Although effective, its use has been limited due to concerns over side effects, including immune system suppression. Further studies are needed to refine its therapeutic applications.